About: Issa F Khouri

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Issa F Khouri Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

University of Texas MD Anderson Cancer Center; University of Nebraska Medical Center; Ohio State University; National Cancer Institute; Yale University; Roswell Park Comprehensive Cancer Center; University of Minnesota; Medical College of Wisconsin;

Attributes	Values
rdf:type	Item
description	University of Texas MD Anderson Cancer Center; University of Nebraska Medical Center; Ohio State University; National Cancer Institute; Yale University; Roswell Park Comprehensive Cancer Center; University of Minnesota; Medical College of Wisconsin; (en)
rdfs:label	Issa F Khouri (de) Issa F Khouri (en) Issa F Khouri (es) Issa F Khouri (fr) Issa F Khouri (gl) Issa F Khouri (it) Issa F Khouri (nl) Issa F Khouri (pt) Issa F Khouri (sv) Issa F Khouri (pt-br)
skos:prefLabel	Issa F Khouri (de) Issa F Khouri (en) Issa F Khouri (es) Issa F Khouri (fr) Issa F Khouri (gl) Issa F Khouri (it) Issa F Khouri (nl) Issa F Khouri (pt) Issa F Khouri (sv) Issa F Khouri (pt-br)
name	Issa F Khouri (de) Issa F Khouri (en) Issa F Khouri (es) Issa F Khouri (fr) Issa F Khouri (gl) Issa F Khouri (it) Issa F Khouri (nl) Issa F Khouri (pt) Issa F Khouri (sv) Issa F Khouri (pt-br)
instance of	wds:Q116176461-E4A4EFB9-A277-454B-8ED3-57EDCCFF432C
instance of	Homo sapiens
Dimensions author ID	wds:Q116176461-D813498F-3018-497F-807A-EB15C88FD7D8
Dimensions author ID	0667650426.15
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q116176461
is author of	Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies Genetically identical twin transplantation for chronic lymphocytic leukemia High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab) Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab Is there an increased rate of additional malignancies in patients with mantle cell lymphoma? Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation Chronic graft-versus-host disease after allogeneic blood stem cell transplantation Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software